STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANRO
  4. [SCHEDULE 13G/A] Alto Neuroscience Inc. SEC Filing

[SCHEDULE 13G/A] Alto Neuroscience Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock ANRO logo
Alto Neuroscienc

NYSE:ANRO

ANRO Rankings

#4718 Ranked by Market Cap
N/A Ranked by Dividends

ANRO Latest News

Oct 3, 2025
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia
Sep 9, 2025
Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia
Aug 18, 2025
Alto Neuroscience to Participate in Upcoming Investor Conferences
Aug 13, 2025
Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Aug 13, 2025
Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

ANRO Latest SEC Filings

Aug 14, 2025
[SCHEDULE 13G/A] Alto Neuroscience Inc. SEC Filing
Aug 14, 2025
[Form 4] Alto Neuroscience Inc. Insider Trading Activity
Aug 14, 2025
[Form 3] Alto Neuroscience Inc. Initial Statement of Beneficial Ownership
Aug 13, 2025
[10-Q] Alto Neuroscience Inc. Quarterly Earnings Report
Aug 13, 2025
[8-K] Alto Neuroscience Inc. Reports Material Event

ANRO Stock Data

119.41M
24.80M
7.48%
64.06%
6.28%
Biotechnology
Pharmaceutical Preparations
Link
United States
MOUNTAIN VIEW